Cargando…
Remdesivir in treating hospitalized patients with COVID-19: A renewed review of clinical trials
Since December 2019, COVID-19 has spread across the world almost through 2.5 years. As of 16 June 2022, the cumulative number of confirmed cases of COVID-19 worldwide has reached 542.62 million, and the death toll has risen to 6.33 million. With the increasing number of deaths, it is urgent to find...
Autores principales: | Wu, Zhenchao, Han, Zhifei, Liu, Beibei, Shen, Ning |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9493488/ https://www.ncbi.nlm.nih.gov/pubmed/36160434 http://dx.doi.org/10.3389/fphar.2022.971890 |
Ejemplares similares
-
Population Pharmacokinetics of Remdesivir and GS-441524 in Hospitalized COVID-19 Patients
por: Leegwater, E., et al.
Publicado: (2022) -
Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a Promising Therapeutic Option for COVID-19?
por: Sisay, Mekonnen
Publicado: (2020) -
Evaluation of safety and effectiveness of remdesivir in treating COVID-19 patients after emergency use authorization study
por: Burhan, Erlina, et al.
Publicado: (2023) -
Incidence and potential risk factors for remdesivir-associated bradycardia in hospitalized patients with COVID-19: A retrospective cohort study
por: Alsowaida, Yazed Saleh, et al.
Publicado: (2023) -
Association between angiotensin-converting enzyme inhibitor-induced cough and the risk of lung cancer: a Mendelian randomization study
por: Yao, Taikang, et al.
Publicado: (2023)